T Seck

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. doi Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
    T Seck
    Merck Research Laboratories, Rahway, NJ, USA
    Int J Clin Pract 64:562-76. 2010
  2. doi Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide
    Thomas L Seck
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, United States
    Diabetes Res Clin Pract 93:e15-7. 2011

Detail Information

Publications2

  1. doi Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
    T Seck
    Merck Research Laboratories, Rahway, NJ, USA
    Int J Clin Pract 64:562-76. 2010
    ..To evaluate the 2-year safety and efficacy of adding sitagliptin or glipizide to ongoing metformin in patients with type 2 diabetes...
  2. doi Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide
    Thomas L Seck
    Merck Sharp and Dohme Corp, Whitehouse Station, NJ, United States
    Diabetes Res Clin Pract 93:e15-7. 2011
    ..5% without hypoglycemia and without an increase in body weight...